Eli Lilly's SWOT analysis: stock soars on GLP-1 success, faces competition challenges
Eli Lilly and Company (NYSE:LLY), a leading pharmaceutical giant with a market capitalization of $724 billion, has been ...
The Motley Fool5d
Move Over Mounjaro. Eli Lilly Has Another Blockbuster Opportunity in the Making, and No One Is Talking About It.
Eli Lilly is experiencing ... and help contribute to the overall picture in a meaningful way. To me, oncology represents a hugely important new area for Lilly, and one that is ripe for disruption ...
Business Insider4d
Eli Lilly's head of obesity talks weight-loss innovations for 2025 — from an Ozempic-like pill to a triple-threat shot
If Eli Lilly has its way, this may be the future of obesity care. Eli Lilly makes some of the most powerful weight-loss drugs in the world. The company has pivoted dramatically over the past ...
Business Insider3d
Morgan Stanley Reaffirms Their Buy Rating on Eli Lilly & Co (LLY)
In a report released today, Terence Flynn from Morgan Stanley reiterated a Buy rating on Eli Lilly & Co (LLY – Research Report), with a price target of $1,146.00. The company’s shares closed ...
Yahoo Finance5d
Move Over Mounjaro. Eli Lilly Has Another Blockbuster Opportunity in the Making, and No One Is Talking About It.
While Novo Nordisk's Ozempic is the most mainstream GLP-1 medication, Eli Lilly (NYSE: LLY) has two blockbuster weight loss drugs of its own: Mounjaro and Zepbound. Mounjaro and Zepbound are by ...
Zacks.com on MSN9h
Eli Lilly (LLY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Wall Street expects a year-over-year increase in earnings on higher revenues when Eli Lilly (LLY) reports results for the quarter ended December 2024. While this widely-known consensus outlook is ...
The INDEPENDENT PRESS AWARD® Gives International Recognition To Melinda Spaulding And Mitch Tull For Finding Insight
Independent Press Award Distinguished Favorite Finding Insight: Discovering the Non-Obvious Obvious Connection to Why People Do What ...
Nasdaq5d
Move Over Mounjaro. Eli Lilly Has Another Blockbuster Opportunity in the Making, and No One Is Talking About It.
While Novo Nordisk's Ozempic is the most mainstream GLP-1 medication, Eli Lilly ... overall picture in a meaningful way. To me, oncology represents a hugely important new area for Lilly, and ...
Seeking Alpha2d
LLY Eli Lilly and Company
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50 ...
Nasdaq6d
March 2026 Options Now Available For Eli Lilly (LLY)
Investors in Eli Lilly (Symbol: LLY) saw new options begin trading today, for the March 2026 expiration. One of the key data points that goes into the price an option buyer is willing to pay ...
Business Insider2d
Eli Lilly Stock , LLY
Earnings Report 5.212 USD Q4 2024 Earnings Release 02/06/2025 Earnings Report 4.918 USD Q1 2025 Earnings Release 05/01/2025 Earnings Report 5.695 USD Q2 2025 Earnings Release 08/07/2025 Earnings ...
Business Today5d
Eli Lilly plans to expand its pipeline to address obesity-related conditions in India, says top executive
To address this, American pharmaceutical giant Eli Lilly is focusing on weight loss medications like Mounjaro (tirzepatide), which has proven effective in managing both obesity and type-2 diabetes.